Health Law Daily Wrap Up, PRESCRIPTION DRUGS—FINAL RULES: CMS locks in Medicare drug negotiation rules for 2029 and beyond, (Nov 9, 2026)

By WK Editorial Staff

The final rule creates a permanent regulatory framework for selecting high-spending drugs, negotiating maximum fair prices, guarding against reformulation strategies, and carrying negotiated prices into Part D coverage and payment.

The Centers for Medicare & Medicaid Services finalized regulations that move the Medicare Drug Price Negotiation Program from time-limited guidance into a durable framework for initial price applicability year 2029 and later years. The rule implements statutory requirements for identifying and ranking eligible drugs, negotiating and renegotiating maximum fair prices, monitoring manufacturer compliance, and coordinating negotiated prices with the Medicare Part D benefit. CMS said the framework is intended to produce greater value for beneficiaries and taxpayers while preserving incentives for pharmaceutical innovation. The rule takes effect December 5, 2026 (Final Rule, 91 Fed. Reg. 72176 (Nov. 9, 2026)).

A permanent framework built from early negotiation cycles

CMS codified policies used for the first three negotiation cycles and revised them to reflect operational experience. The regulations establish rules for qualification as a single-source drug, drug selection, manufacturer agreements, submission of manufacturer-specific data, consideration of therapeutic alternatives, negotiation meetings, offers and counteroffers, publication of agreed-upon prices, and renegotiation. CMS also established a 10-day process for manufacturers to identify suggested errors in specified agency determinations. According to CMS’s fact sheet, the agency acted because Congress’s authority to implement the program through program instruction and guidance expires after 2028, requiring regulations for the fourth and later negotiation cycles.

For 2029 and each later initial price applicability year, CMS may select as many as 20 drugs covered under Part D, payable under Part B, or both. The agency ranks negotiation-eligible drugs using combined Part B and Part D expenditures. For Part B drugs, CMS includes estimated Medicare Advantage utilization based on encounter data and Original Medicare payment amounts. The approach aligns selection with total Medicare spending rather than limiting the comparison to one benefit.

Aggregation targeted fixed-combination reformulations

The rule changes how CMS treats a narrow category of fixed-combination products. When a fixed-combination drug shared one or more active components with another product held by the same new drug application or biologics license application holder, CMS will aggregate the products if the added component created a new formulation and enabled an alternative route of administration for the shared component. CMS will then treat all dosage forms and strengths as one potential qualifying single-source drug.

CMS said the policy addresses a program-integrity risk created when a manufacturer could shift use from an original product to a reformulation and thereby delay selection or avoid applying the maximum fair price. The agency tied the policy to statutory directions to aggregate dosage forms, strengths, and new formulations and to apply one maximum fair price across a selected drug. CMS acknowledged that alternative routes of administration can provide clinical value, but it based aggregation on the statutory framework rather than a judgment that the products were clinically equivalent. The CMS press release similarly describes the policy as preventing incentives to move patients to a new formulation to circumvent the negotiated price.

Competition and eligibility determinations received clearer standards

CMS requires more than nominal generic or biosimilar availability before a drug loses negotiation eligibility or selected-drug status. The agency defines Bona Fide Marketing through a holistic assessment of meaningful, ongoing competition and specifies the information and review points it will use. CMS also clarified the treatment of drugs that previously qualified for the orphan-drug exclusion. A drug qualifies for that exclusion only when all of its approved indications are for designated rare diseases or conditions, and the rule addresses how withdrawn indication approvals affect later eligibility.

Negotiation mechanics balanced a statutory ceiling with a biotech floor

The rule requires CMS to establish one maximum fair price based on a 30-day equivalent supply and to apply that price across dosage forms and strengths. It also implements the Temporary Floor for Small Biotech Drugs for eligible drugs negotiated or renegotiated for 2029 or 2030. The floor prevents CMS from offering or accepting a counteroffer below the statutory amount. CMS modified the adjusted-ceiling calculation for cases in which the otherwise applicable statutory ceiling falls below the temporary floor, preserving the floor’s operative effect while maintaining the rule’s ceiling methodology. The CMS fact sheet identifies the temporary floor as a new statutory protection following expiration of the earlier small-biotech exception from negotiation eligibility.

Part D rules connected negotiated prices to formulary access

CMS requires Part D plans to include each covered selected drug on their formularies while a maximum fair price is in effect and limits the negotiated price used to pay dispensing entities to no more than the maximum fair price plus dispensing fees. The formulary requirement extends to all covered dosage forms and strengths subject to the negotiated price, subject to existing rules permitting certain formulary changes.

CMS declined to create selected-drug-specific tier-placement or utilization-management standards. It reasoned that existing Part D requirements already require clinical decisions to rest on scientific evidence and standards of practice. The agency said it will continue reviewing nonpreferred placement, higher cost sharing than comparable nonselected brands, step therapy favoring a nonselected brand, and more restrictive prior authorization or other utilization controls. Selected-drug status reflects expenditure and statutory eligibility criteria, CMS emphasized, not a determination of clinical superiority or inferiority.

Compliance rules backed the program with corrective action and penalties

The final rule authorizes CMS to monitor compliance, request corrective action, and impose civil money penalties where the statute allowed. Penalty provisions cover specified violations of negotiation agreements, knowing submission of false information, and failures involving rebates owed after a biosimilar-delay request. Together, the oversight provisions support the agency’s stated goal, described in the CMS press release, of giving manufacturers and patients a clearer path as the program expands to additional high-cost drugs.

MainStory: TopStory FinalRules AgencyNews ReimbursementNews ComplianceNews DrugNews CMSNews PartBNews PartDNews PrescriptionDrugNews